Here are five points:
1. Some pharmaceutical companies, like Washington, D.C.-based PhRMA, don’t view the proposal favorably.
2. A PhRMA spokesperson argued price transparency for R&D alludes to future price controls.
3. With rising drugs costs, the idea involves understanding how much it takes to develop a drug to understand how much a company should charge for a drug.
4. Drug companies argue it’s not that simple. The companies consider three factors when pricing a drug: competition, the price consumers will pay and the value patients receive from the drug.
5. Drug companies are paid based on the patient outcomes their drugs provide. To them, focusing on R&D costs is missing the point.
More articles on coding, billing & collections:
National Medical Billing Services Lisa Rock named ‘Top Women Business Owners’ by SBM
Horizon BCBS of New Jersey awards physicians $3M in bonuses — 4 highlights
BCBS considers pulling out of ACA leaving nearly 300,000 North Carolinians hanging in the balance: 4 points
